AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

QTc Study GSK573719+GW642444

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo Moxifloxacin
Drug: Moxifloxacin
Drug: Placebo DPI
Drug: GSK573719/Vilanterol 125/25mcg
Drug: GSK573719
Drug: GSK573719/Vilanterol 500/100mcg

First Posted Date: 2012-01-30

Last Posted Date: 2017-06-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 100

Registration Number: NCT01521377

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Procedure: Spirometry

First Posted Date: 2012-01-25

Last Posted Date: 2017-09-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 3500

Registration Number: NCT01516528

Locations: 🇪🇸
GSK Investigational Site, Valencia, Spain

Japanese phase1 Study of Belimumab (IV vs SC)

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: GSK1550188 IV
Drug: GSK1550188 SC

First Posted Date: 2012-01-24

Last Posted Date: 2017-06-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT01516450

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD

Not Applicable

Completed

Conditions: Respiratory Disorders

Interventions: Procedure: Blood collection
Procedure: Swab collection
Procedure: Sputum collection

First Posted Date: 2012-01-24

Last Posted Date: 2017-05-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 73

Registration Number: NCT01516437

Locations: 🇧🇪
GSK Investigational Site, Liège, Belgium

Serological Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in Stools of Infants Following Administration of Rotarix™

Completed

Conditions: Evidence of PCV-1 Replication and/or Immune Response to the PCV-1 in HRV Vaccinated Infants
Rotavirus Infection

Interventions: Procedure: Stool sample
Procedure: Serum sample

First Posted Date: 2012-01-18

Last Posted Date: 2017-05-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01511133

A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema

Phase 2

Completed

Conditions: Retinopathy, Diabetic

Interventions: Drug: placebo
Drug: darapladib

First Posted Date: 2012-01-10

Last Posted Date: 2016-11-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 54

Registration Number: NCT01506895

Locations: 🇳🇱
GSK Investigational Site, Rotterdam, Netherlands

Provoked Craving Assessment

Phase 2

Completed

Conditions: Smoking Dependence
Smoking

Interventions: Drug: oral nicotine
Drug: Placebo

First Posted Date: 2012-01-10

Last Posted Date: 2019-08-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 323

Registration Number: NCT01506908

Locations: 🇺🇸
Los Angeles Clinical Trials, Burbank, California, United States

Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children

Phase 3

Completed

Conditions: Rubella
Mumps
Measles
Varicella

Interventions: Biological: PriorixTetra™
Biological: Meningitec

First Posted Date: 2012-01-09

Last Posted Date: 2018-08-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 716

Registration Number: NCT01506193

Locations: 🇮🇹
GSK Investigational Site, Ragusa (RG), Sicilia, Italy

A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: GW685698X (fluticasone furoate) 100mcg Morning
Drug: GW685698X (fluticasone furoate) 100mcg Evening
Drug: GW685698X (fluticasone furoate) 250mcg Evening
Drug: Placebo